{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:06:04Z","timestamp":1784189164338,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transition-age (TA) adults are less likely than adults aged 26 and older to receive medications for opioid use disorder (MOUD), and among those treated, disproportionately receive naltrexone over more effective agonist MOUD (buprenorphine and methadone). Given that prescribers ultimately determine medication selection, understanding how age influences their clinical decisions is essential to addressing these disparities. This study examines how prescribers incorporate age into MOUD prescribing decisions for this developmentally vulnerable population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using 2022 New York State Medicaid claims, we identified MOUD prescribers with substantial experience (treating n\u2009\u2265\u20095 TA adults) and conducted semi-structured interviews with 18 outpatient prescribers (MD\/DOs, NPs, PAs) from diverse geographic and clinical settings. We applied an inductive thematic analysis approach to explore how prescribers incorporated age and age-related factors into their clinical decision-making around MOUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most prescribers did not endorse chronological age as a factor influencing their prescribing patterns, but rather described tailoring treatment based on age-related factors more commonly seen in TA adults. These included developmental characteristics (perceived lack of commitment, peer influence), socioeconomic barriers (e.g., unreliable transportation leading to missed appointments), family influence, and concerns about MOUD dependence. In response to these age-related factors, prescribers implemented harm-reduction principles by adjusting MOUD type prescribing to accommodate TA adults' life-stage realities. In contrast, a small subset of prescribers explicitly cited chronological age as directly influencing MOUD prescribing, expressing hesitations about initiating buprenorphine or referring TA adults for methadone due to long-term dependence concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest two key mechanisms through which age may influence MOUD prescribing disparities among TA adults: (1) prescribers' responses to age-related life-stage challenges (e.g., developmental and social factors, structural barriers) and (2) explicit prescriber age-based hesitancy about initiating long-term agonist maintenance in younger patients. The first mechanism appeared more influential than explicit hesitancy. These mechanisms may help explain documented disparities in MOUD type prescribed. Addressing these disparities may require multi-level interventions: prescriber education affirming agonist MOUD effectiveness for TA adults, efforts to reduce MOUD misconceptions among patients and families, peer-based approaches that leverage social influence positively, and flexible harm-reduction-oriented clinic policies that accommodate structural barriers while supporting access to evidence-based MOUD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-026-01467-1","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:23:44Z","timestamp":1779449024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Too young for medication? prescriber perspectives on how age shapes medication for opioid use disorder prescribing in transition-age adults"],"prefix":"10.1186","volume":"23","author":[{"given":"Diego","family":"Renteria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetayo","family":"Fawole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Aleksanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugy","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Liebmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sueun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashly E.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan O\u2019","family":"Grady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Drury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Kawola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"del Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat","family":"Lincourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Neighbors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"1467_CR1","doi-asserted-by":"crossref","unstructured":"Paul N, Kennedy AJ, Taubenberger S, Chang JC, Hacker K. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates. Subst Abuse [Internet]. 2022 [cited 2025 Jul 22];43(1):742\u20138. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10960355\/","DOI":"10.1080\/08897077.2021.2007518"},{"key":"1467_CR2","doi-asserted-by":"crossref","unstructured":"Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder. Ann Fam Med [Internet]. 2015 Jan [cited 2025 Jul 22];13(1):23\u20136. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4291261\/","DOI":"10.1370\/afm.1735"},{"issue":"1","key":"1467_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00918-3","volume":"20","author":"B Franz","year":"2023","unstructured":"Franz B, Dhanani LY, Hall OT, Brook DL, Simon JE, Miller WC. Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US. Harm Reduct J. 2023;20(1):180. https:\/\/doi.org\/10.1186\/s12954-023-00918-3.","journal-title":"Harm Reduct J"},{"issue":"3","key":"1467_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3821","volume":"5","author":"PM Mauro","year":"2022","unstructured":"Mauro PM, Gutkind S, Annunziato EM, Samples H. Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019. JAMA Netw Open. 2022;5(3):e223821. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.3821.","journal-title":"JAMA Netw Open"},{"key":"1467_CR5","doi-asserted-by":"crossref","unstructured":"Becker SJ, Scott K, Helseth SA, Danko KJ, Balk EM, Saldanha IJ, et al. Effectiveness of medication for opioid use disorders in transition-age youth: A systematic review. J Subst Abuse Treat [Internet]. 2022 Jan 1 [cited 2025 Jan 2];132:108494. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0740547221002208","DOI":"10.1016\/j.jsat.2021.108494"},{"issue":"357","key":"1467_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550","volume":"26","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;26(357):j1550.","journal-title":"BMJ"},{"key":"1467_CR7","doi-asserted-by":"crossref","unstructured":"Welsh JW, Dennis ML, Funk R, Mataczynski MJ, Godley MD. Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults. J Subst Abuse Treat [Internet]. 2022 Jan [cited 2025 Jul 23];132:108584. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8671231\/","DOI":"10.1016\/j.jsat.2021.108584"},{"key":"1467_CR8","doi-asserted-by":"crossref","unstructured":"Chadi N, Bagley SM, Hadland SE. Addressing Adolescents\u2019 and Young Adults\u2019 Substance Use Disorders. Med Clin North Am [Internet]. 2018 Jul 1 [cited 2024 Dec 23];102(4):603\u201320. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0025712518300191","DOI":"10.1016\/j.mcna.2018.02.015"},{"issue":"7","key":"1467_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.addbeh.2012.02.014","volume":"37","author":"AL Stone","year":"2012","unstructured":"Stone AL, Becker LG, Huber AM, Catalano RF. Review of risk and protective factors of substance use and problem use in emerging adulthood. Addict Behav. 2012;37(7):747\u201375.","journal-title":"Addict Behav"},{"issue":"7","key":"1467_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.22303","volume":"6","author":"T Gomes","year":"2023","unstructured":"Gomes T, Ledlie S, Tadrous M, Mamdani M, Paterson JM, Juurlink DN. Trends in Opioid Toxicity-Related Deaths in the US Before and After the Start of the COVID-19 Pandemic, 2011\u20132021. JAMA Netw Open. 2023;6(7):e2322303.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"1467_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002922","volume":"16","author":"JD Hudgins","year":"2019","unstructured":"Hudgins JD, Porter JJ, Monuteaux MC, Bourgeois FT. Prescription opioid use and misuse among adolescents and young adults in the United States: a national survey study. PLoS Med. 2019;16(11):e1002922.","journal-title":"PLoS Med"},{"key":"1467_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04813-5","author":"D Xu","year":"2025","unstructured":"Xu D, Li J, Yan H. The rising tide of opioid use disorder: analyzing 30 years of epidemiological trends and socioeconomic factors in the U.S. Naunyn Schmiedebergs Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-04813-5.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"1467_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","volume":"76","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiat. 2019;76(2):208\u201316. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3126.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"1467_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.45691","volume":"5","author":"SG Weiner","year":"2022","unstructured":"Weiner SG, El Ibrahimi S, Hendricks MA, Hallvik SE, Hildebran C, Fischer MA, et al. Factors associated with opioid overdose after an initial opioid prescription. JAMA Netw Open. 2022;5(1):e2145691. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.45691.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"1467_CR15","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/archpsyc.62.10.1157","volume":"62","author":"LA Marsch","year":"2005","unstructured":"Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005;62(10):1157\u201364.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"1467_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","volume":"171","author":"SE Hadland","year":"2017","unstructured":"Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001\u20132014. JAMA Pediatr. 2017;171(8):747\u201355.","journal-title":"JAMA Pediatr"},{"issue":"12","key":"1467_CR17","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1111\/add.15959","volume":"117","author":"M Burns","year":"2022","unstructured":"Burns M, Tang L, Chang CCH, Kim JY, Ahrens K, Allen L, et al. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study. Addiction. 2022;117(12):3079\u201388.","journal-title":"Addiction"},{"key":"1467_CR18","first-page":"1","volume":"23","author":"P Treitler","year":"2025","unstructured":"Treitler P, Samples H, Hermida R, Miles J, Stone EM, Crystal S. Pharmacotherapy and overdose risk following new opioid use disorder diagnosis among Medicaid beneficiaries. Am J Drug Alcohol Abuse. 2025;23:1\u201311.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"9","key":"1467_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiat. 2021;78(9):979\u201393. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0976.","journal-title":"JAMA Psychiat"},{"key":"1467_CR20","doi-asserted-by":"crossref","unstructured":"Dowell D, Brown S, Gyawali S, Hoenig J, Ko J, Mikosz C, et al. Treatment for Opioid Use Disorder: Population Estimates \u2014 United States, 2022. Morb Mortal Wkly Rep [Internet]. 2024 Jun 27 [cited 2026 Feb 2];73(25):567\u201374. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11254342\/","DOI":"10.15585\/mmwr.mm7325a1"},{"key":"1467_CR21","doi-asserted-by":"crossref","unstructured":"Bagley SM, Larochelle MR, Xuan Z, Wang N, Patel A, Bernson D, et al. Characteristics of and Receipt of Medication Treatment among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. Ann Emerg Med [Internet]. 2020 Jan [cited 2024 Dec 24];75(1):29\u201338. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7953238\/","DOI":"10.1016\/j.annemergmed.2019.07.030"},{"key":"1467_CR22","doi-asserted-by":"publisher","unstructured":"Babu KM, Brent J, Juurlink DN. Prevention of Opioid Overdose. N Engl J Med [Internet]. 2019 Jun 6 [cited 2026 Feb 2];380(23):2246\u201355. Available from: https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMra1807054","DOI":"10.1056\/NEJMra1807054"},{"issue":"21","key":"1467_CR23","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1001\/jama.2024.16954","volume":"332","author":"B Nosyk","year":"2024","unstructured":"Nosyk B, Min JE, Homayra F, Kurz M, Guerra-Alejos BC, Yan R, et al. Buprenorphine\/Naloxone vs Methadone for the treatment of opioid use disorder. JAMA. 2024;332(21):1822\u201331. https:\/\/doi.org\/10.1001\/jama.2024.16954.","journal-title":"JAMA"},{"key":"1467_CR24","unstructured":"Frank CJ, Morrison L. Harm Reduction for Patients With Substance Use Disorders. Am Fam Physician [Internet]. 2022 Jan [cited 2026 Feb 5];105(1):90\u20132. Available from: https:\/\/www.aafp.org\/pubs\/afp\/issues\/2022\/0100\/p90.html"},{"key":"1467_CR25","doi-asserted-by":"crossref","unstructured":"Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerd\u00e1 M. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019\u201d. Int J Drug Policy [Internet]. 2022 Dec [cited 2026 Feb 6];110:103786. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10976290\/","DOI":"10.1016\/j.drugpo.2022.103786"},{"issue":"5","key":"1467_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10488-013-0528-y","volume":"42","author":"LA Palinkas","year":"2015","unstructured":"Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Adm Policy Ment Health. 2015;42(5):533\u201344. https:\/\/doi.org\/10.1007\/s10488-013-0528-y.","journal-title":"Adm Policy Ment Health"},{"issue":"8","key":"1467_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297567","volume":"19","author":"J Aleksanyan","year":"2024","unstructured":"Aleksanyan J, Choi S, Lincourt P, Burke C, Ramsey KS, Hussain S, et al. Lost in transition: a protocol for a retrospective, longitudinal cohort study for addressing challenges in opioid treatment for transition-age adults. PLoS ONE. 2024;19(8):e0297567.","journal-title":"PLoS ONE"},{"key":"1467_CR28","doi-asserted-by":"crossref","unstructured":"Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant [Internet]. 2018 [cited 2025 Apr 2];52(4):1893\u2013907. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5993836\/","DOI":"10.1007\/s11135-017-0574-8"},{"key":"1467_CR29","doi-asserted-by":"publisher","unstructured":"Kallio H, Pietil\u00e4 AM, Johnson M, Kangasniemi M. Systematic methodological review: developing a framework for a qualitative semi-structured interview guide. J Adv Nurs [Internet]. 2016 Dec 1 [cited 2025 Apr 14];72(12):2954\u201365. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/jan.13031","DOI":"10.1111\/jan.13031"},{"key":"1467_CR30","doi-asserted-by":"crossref","unstructured":"Paul N, Kennedy AJ, Taubenberger S, Chang JC, Hacker K. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates. Subst Abuse [Internet]. 2022 [cited 2025 Feb 17];43(1):742\u20138. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10960355\/","DOI":"10.1080\/08897077.2021.2007518"},{"key":"1467_CR31","doi-asserted-by":"crossref","unstructured":"Buchholz C, Bell LA, Adatia S, Bagley SM, Wilens TE, Nurani A, et al. Medications for Opioid Use Disorder for Youth: Patient, Caregiver, and Clinician Perspectives. J Adolesc Health [Internet]. 2024 Feb 1 [cited 2025 Feb 25];74(2):320\u20136. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1054139X23004603","DOI":"10.1016\/j.jadohealth.2023.08.047"},{"key":"1467_CR32","doi-asserted-by":"publisher","unstructured":"Nowell LS, Norris JM, White DE, Moules NJ. Thematic Analysis: Striving to Meet the Trustworthiness Criteria. Int J Qual Methods [Internet]. 2017 Dec 1 [cited 2025 Feb 25];16(1):1609406917733847. Available from: https:\/\/doi.org\/10.1177\/1609406917733847","DOI":"10.1177\/1609406917733847"},{"key":"1467_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/1609406919899220","volume":"19","author":"C O\u2019Connor","year":"2020","unstructured":"O\u2019Connor C, Joffe H. Intercoder reliability in qualitative research: debates and practical guidelines. Int J Qual Methods. 2020;19:1609406919899220. https:\/\/doi.org\/10.1177\/1609406919899220.","journal-title":"Int J Qual Methods"},{"key":"1467_CR34","unstructured":"New York Executive Law \u00a7 481(7) [Internet]. 2014 [cited 2025 Feb 26]. Available from: https:\/\/www.nysenate.gov\/legislation\/laws\/EXC\/481"},{"key":"1467_CR35","doi-asserted-by":"crossref","unstructured":"Hadland SE, Aalsma MC, Akg\u00fcl S, Alinsky RH, Bruner A, Chadi N, et al. Medication for Adolescents and Young Adults with Opioid Use Disorder. J Adolesc Health Off Publ Soc Adolesc Med [Internet]. 2021 Mar [cited 2024 Dec 24];68(3):632\u20136. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7902443\/","DOI":"10.1016\/j.jadohealth.2020.12.129"},{"key":"1467_CR36","doi-asserted-by":"crossref","unstructured":"Carl A, Pasman E, Broman MJ, Lister JJ, Agius E, Resko SM. Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug Alcohol Depend Rep [Internet]. 2023 Feb 7 [cited 2025 Apr 1];6:100138. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10040326\/","DOI":"10.1016\/j.dadr.2023.100138"},{"key":"1467_CR37","doi-asserted-by":"crossref","unstructured":"Sabin JA, Marini M, Nosek BA. Implicit and Explicit Anti-Fat Bias among a Large Sample of Medical Doctors by BMI, Race\/Ethnicity and Gender. PLoS ONE [Internet]. 2012 Nov 7 [cited 2025 Apr 1];7(11):e48448. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3492331\/","DOI":"10.1371\/journal.pone.0048448"},{"key":"1467_CR38","doi-asserted-by":"publisher","unstructured":"FitzGerald C, Hurst S. Implicit bias in healthcare professionals: a systematic review. BMC Med Ethics [Internet]. 2017 Mar 1 [cited 2025 Apr 1];18(1):19. Available from: https:\/\/doi.org\/10.1186\/s12910-017-0179-8","DOI":"10.1186\/s12910-017-0179-8"},{"key":"1467_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/11782218221103859","volume":"16","author":"J Dickson-Gomez","year":"2022","unstructured":"Dickson-Gomez J, Spector A, Weeks M, Galletly C, McDonald M, Green Montaque HD. \u201cYou\u2019re not supposed to be on it forever\u201d: medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids. Subst Abuse Res Treat. 2022;16:11782218221103859.","journal-title":"Subst Abuse Res Treat"},{"key":"1467_CR40","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.socscimed.2019.05.027","volume":"232","author":"EF Madden","year":"2019","unstructured":"Madden EF. Intervention stigma: how medication-assisted treatment marginalizes patients and providers. Soc Sci Med. 2019;232:324\u201331.","journal-title":"Soc Sci Med"},{"issue":"6","key":"1467_CR41","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-071147","volume":"156","author":"SE Hadland","year":"2025","unstructured":"Hadland SE, Kimmel SD, Yan S, Bettano AL, Lo-Ciganic WH, Bagley SM, et al. Buprenorphine Treatment Duration and Adherence Among Youth and Subsequent Health Outcomes. Pediatrics. 2025;156(6):e2025071147.","journal-title":"Pediatrics"},{"key":"1467_CR42","unstructured":"Federal Register\u202f:: Medications for the Treatment of Opioid Use Disorder [Internet]. [cited 2025 Feb 17]. Available from: https:\/\/www.federalregister.gov\/documents\/2024\/02\/02\/2024-01693\/medications-for-the-treatment-of-opioid-use-disorder"},{"issue":"6","key":"1467_CR43","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/fampra\/cmae044","volume":"41","author":"S Mazzarelli","year":"2024","unstructured":"Mazzarelli S, Blewer AL, \u00d8stbye T, Rhodes K, Plasencia G, Hart L, et al. Impact of implementing primary care-based medication for opioid use disorder on provider and staff perceptions. Fam Pract. 2024;41(6):1018\u201324.","journal-title":"Fam Pract"},{"key":"1467_CR44","doi-asserted-by":"crossref","unstructured":"Fishman M, Wenzel K, Gauthier P, Borodovsky J, Murray O, Subramaniam G, et al. Engagement, initiation, and retention in medication treatment for opioid use disorder among young adults: A narrative review of challenges and opportunities. J Subst Use Addict Treat [Internet]. 2024 Nov 1 [cited 2025 Feb 17];166:209352. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S294987592400064X","DOI":"10.1016\/j.josat.2024.209352"},{"key":"1467_CR45","doi-asserted-by":"crossref","unstructured":"Bagley SM, Schoenberger SF, dellaBitta V, Lunze K, Barron K, Hadland SE, et al. Ambivalence and stigma beliefs about medication treatment among young adults with opioid use disorder: a qualitative exploration of young adults\u2019 perspectives. J Adolesc Health Off Publ Soc Adolesc Med [Internet]. 2023 Jan [cited 2025 Feb 17];72(1):105\u201310. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10077517\/","DOI":"10.1016\/j.jadohealth.2022.08.026"},{"key":"1467_CR46","unstructured":"Bonnie RJ, Stroud C, Breiner H, Committee on Improving the Health S, Board on Children Y, Medicine I of, et al. Young Adults in the 21st Century. In: Investing in the Health and Well-Being of Young Adults [Internet]. National Academies Press (US); 2015 [cited 2026 Feb 4]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK284782\/"},{"key":"1467_CR47","doi-asserted-by":"crossref","unstructured":"Moss HB, Ge S, Trager E, Saavedra M, Yau M, Ijeaku I, et al. Risk for Substance Use Disorders in young adulthood: Associations with developmental experiences of homelessness, foster care, and adverse childhood experiences. Compr Psychiatry [Internet]. 2020 Jul 1 [cited 2026 Feb 4];100:152175. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0010440X20300171","DOI":"10.1016\/j.comppsych.2020.152175"},{"key":"1467_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cogdev.2017.03.002","volume":"43","author":"M Kne\u017eevi\u0107","year":"2017","unstructured":"Kne\u017eevi\u0107 M, Marinkovi\u0107 K. Neurodynamic correlates of response inhibition from emerging to mid adulthood. Cogn Dev. 2017;43:106\u201318.","journal-title":"Cogn Dev"},{"key":"1467_CR49","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.neubiorev.2016.09.030","volume":"71","author":"S Dom\u00ednguez-Salas","year":"2016","unstructured":"Dom\u00ednguez-Salas S, D\u00edaz-Batanero C, Lozano-Rojas OM, Verdejo-Garc\u00eda A. Impact of general cognition and executive function deficits on addiction treatment outcomes: systematic review and discussion of neurocognitive pathways. Neurosci Biobehav Rev. 2016;71:772\u2013801.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"1467_CR50","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1037\/pag0000790","volume":"39","author":"JJ Castrellon","year":"2024","unstructured":"Castrellon JJ, Zald DH, Samanez-Larkin GR, Seaman KL. Adult age-related differences in susceptibility to social conformity pressures in self-control over daily desires. Psychol Aging. 2024;39(1):102\u201312.","journal-title":"Psychol Aging"},{"key":"1467_CR51","unstructured":"Bureau of Labor Statistics [Internet]. [cited 2025 Feb 17]. A-10. Unemployment rates by age, sex, and marital status, seasonally adjusted. Available from: https:\/\/www.bls.gov\/web\/empsit\/cpseea10.htm"},{"key":"1467_CR52","doi-asserted-by":"crossref","unstructured":"Grubb LK. Personal and Socioeconomic Determinants in Medication-assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults. Clin Ther [Internet]. 2019 Sep 1 [cited 2025 Feb 17];41(9):1669\u201380. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0149291819303923","DOI":"10.1016\/j.clinthera.2019.07.019"},{"key":"1467_CR53","unstructured":"White WL, Scott CK, Dennis ML, Boyle MG. It\u2019s Time to Stop Kicking People Out of Addiction Treatment. Couns Deerfield Beach Fla [Internet]. 2005 Apr [cited 2025 Feb 17];6(2):12\u201325. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6338434\/"},{"key":"1467_CR54","doi-asserted-by":"crossref","unstructured":"Fiori KP, Heller CG, Rehm CD, Parsons A, Flattau A, Braganza S, et al. Unmet Social Needs and No-Show Visits in Primary Care in a US Northeastern Urban Health System, 2018\u20132019. Am J Public Health [Internet]. 2020 Jul [cited 2025 Apr 1];110(Suppl 2):S242\u201350. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7362703\/","DOI":"10.2105\/AJPH.2020.305717"},{"key":"1467_CR55","doi-asserted-by":"crossref","unstructured":"Hogue A, Becker SJ, Wenzel K, Henderson CE, Bobek M, Levy S, et al. Family Involvement in Treatment and Recovery for Substance Use Disorders among Transition-Age Youth: Research Bedrocks and Opportunities. J Subst Abuse Treat [Internet]. 2021 Oct [cited 2025 Aug 14];129:108402. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8380649\/","DOI":"10.1016\/j.jsat.2021.108402"},{"key":"1467_CR56","unstructured":"Arag\u00e3o RM Kim Parker, Juliana Menasce Horowitz and Carolina. Parents, Young Adult Children and the Transition to Adulthood [Internet]. Pew Research Center. 2024 [cited 2025 Aug 14]. Available from: https:\/\/www.pewresearch.org\/social-trends\/2024\/01\/25\/parents-young-adult-children-and-the-transition-to-adulthood\/"},{"key":"1467_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2024.209512","volume":"167","author":"NP Porter","year":"2024","unstructured":"Porter NP, Dunnsue S, Hammond C, MacLean A, Bobek M, Watkins M, et al. \u201cI need as much support as I can get\u201d: a qualitative study of young adult perspectives on family involvement in treatment for opioid use disorder. J Subst Use Addict Treat. 2024;167:209512.","journal-title":"J Subst Use Addict Treat"},{"key":"1467_CR58","doi-asserted-by":"crossref","unstructured":"Bagley SM, Schoenberger SF, dellaBitta V, Lunze K, Barron K, Hadland SE, et al. An Exploration of Young Adults With Opioid Use Disorder and How Their Perceptions of Family Members\u2019 Beliefs Affects Medication Treatment. J Addict Med [Internet]. 2022 [cited 2025 Feb 17];16(6):689\u201394. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9653106\/","DOI":"10.1097\/ADM.0000000000001001"},{"issue":"11","key":"1467_CR59","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","volume":"172","author":"SE Hadland","year":"2018","unstructured":"Hadland SE, Bagley SM, Rodean J, Silverstein M, Levy S, Larochelle MR, et al. Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder. JAMA Pediatr. 2018;172(11):1029\u201337. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.2143. ([cited 2026 Feb 5]).","journal-title":"JAMA Pediatr"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01467-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:29:58Z","timestamp":1784186998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01467-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1467"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01467-1","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"120"}}